Doctronic has raised $40 million in Series B funding to expand its AI-powered doctor platform, bringing its total funding to $65 million. The round was co-led by Abstract and Lightspeed Venture Partners, with participation from existing investors including Seven Stars, Union Square Ventures, Tusk Ventures and Mantis. The company previously secured $20 million in Series A funding and an additional $5 million from Union Square Ventures.
Based in New York, Doctronic offers a HIPAA-compliant platform that provides users with 24/7 access to a free personal AI doctor capable of autonomously making clinical decisions. The system responds to medical questions with detailed explanations and dynamically asks follow-up clinical questions to guide assessments. In addition to its AI consultations, the platform connects patients to licensed physicians via video visits for either a standard insurance copay or a flat $39 fee for uninsured users.
The company plans to use the new capital to expand into pediatrics and deepen partnerships with academic medical centers, payers, digital health platforms and hospital systems. Executives position the platform as a digital front door for health systems, helping route patients efficiently while keeping care within network, and as a predictable-cost primary care solution for insurers.
Doctronic has also gained regulatory traction. In January, the state of Utah announced a partnership allowing the company’s autonomous AI system to legally renew prescriptions for patients with chronic conditions, making it the first AI platform authorised to prescribe routine refills in that context. The company says it is in discussions with regulators in other states to expand these capabilities.
At the federal level, proposed legislation known as the “Healthy Technology Act of 2025,” introduced by Representative David Schweikert, would formally recognise AI systems as practitioners licensed to prescribe FDA-approved drugs if enacted. The bill has been referred to the House Committee on Energy and Commerce.
Click here to read the original news story.